Johnson & Johnson wins FDA approval for Simponi

04/27/2009 | Los Angeles Times (tiered subscription model)

The FDA has cleared golimumab, a rheumatoid arthritis drug to be sold by Johnson & Johnson and Schering-Plough under the brand Simponi. The treatment, which requires fewer injections than J&J's blockbuster drug Remicade, also gained U.S. approval for use in psoriatic arthritis and a form of spinal arthritis called ankylosing spondylitis.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA